RecruitingPhase 4NCT07174349

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Sponsor

Mayo Clinic

Enrollment

20 participants

Start Date

Apr 10, 2026

Study Type

INTERVENTIONAL

Conditions

Urinary Retention Postoperative

Summary

The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.

Eligibility

Min Age: 35 Years

Inclusion Criteria6

Cervical Laminectomy
Cervical Posterior Fusion
Cervical Anterior/Posterior Fusion
Lumbar Laminectomy
Lumbar Posterolateral Fusion
Lumbar Interbody Fusion

Exclusion Criteria17

Cervical Anterior Discectomy and Fusion
Cervical Anterior Corpectomy
Cervical Posterior Discectomy
Cervical Foraminotomy
Lumbar Discectomy (METRx or Open)
Lumbar Foraminotomy
Lumbar Anterior Fusion
Myelopathy with bladder dysfunction
Patients currently taking an alpha-antagonist
o The following drugs are alpha antagonists: alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine.
Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist
History of prostatectomy or urologic surgery involving the bladder or urethra
Severe liver disease or end-stage renal disease
Patients taking strong inhibitors of CYP3A4
o The following drugs are strong inhibitors of CYP3A4: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir/ritonavir, and conivaptan.
Mental disability or prisoner
Pregnancy (for anesthesia purposes)

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUroselective alpha-1-adrenergic receptor antagonist

Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)

OTHERPlacebo

Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)